The IgG1/G2 subclass shift – a sensitive, tissue non-specific marker for malignancy. Diagnostic performance with squamous cell carcinoma of the head and neck

Article metrics

Summary

A significant decrease in %IgG1 accompanied by an increase in %IgG2 in total serum IgG has been previously reported as a highly sensitive marker for detecting early stages of carcinomas of various localizations. Here we investigated the question as to whether this phenomenon is also observed in sera of patients with squamous cell carcinoma of the head–neck region (SCC-HN), and to evaluate its diagnostic performance in the post-operative monitoring. Using quantitative affinity chromatography, serum concentrations of IgG1, IgG2 and total IgG were determined in 81 patients with different stages of primary and untreated SCC-HN, in 51 SCC-HN patients in post-therapeutical follow up, and in 33 patients with organ matched benign diseases. The data were compared with a total of 174 healthy controls. It was found that (i) 105 SCC-HN patients exhibited a mean value of 56.0 ± 0.7% IgG1, which likewise differed from healthy controls (63.2 ± 0.5) and benign diseases (61.5 ± 1.0) with P < 0.0005, (ii) sensitivities and specificities for discriminating primary malignancies from healthy controls were 70 and 74% respectively, and from benign diseases 65 and 76%, (iii) highest sensitivities and specificities were observed with post-therapeutic cases suffering from tumour recurrence (88% and 75%) or patients with distant metastases (87% and 86%), (iv) apparently tumour-free post-therapeutic patients showed a mean %IgG1 not different from the normal value. The decrease in %IgG1 accompanied by increased %IgG2 is an efficient, sensitive and early marker of SCC-HN, which appears particularly useful for the post-therapeutic monitoring.

Change history

  • 16 November 2011

    This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication

References

  1. Clasen, B., Roettger, D., Senekowitsch, R. & Menz, E. (1988). Squamous cell carcinoma antigen (SCC) – Derzeitige klinische Wertigkeit eines Tumormarkers bei Kopf-Hals-Karzinomen, Zwischenergebnisse einer prospektiven Studie nach 12 Monaten. Laryng Rhinol Otol 67: 420–425.

  2. Dreyfuss, A. I., Clark, J. R. & Andersen, J. W. (1992). Lipid-associated sialic acid, squamous cell carcinoma antigen, carcinoembryonic antigen and lactic dehydrogenase level as tumor markers in squamous cell carcinoma of head and neck. Cancer 70: 2499–2503.

  3. Eibling, C. D. E., Johnson, J. T. & Wagner, R. L. (1989). SCC-RIA in the diagnosis of squamous cell carcinoma of the head and neck. Laryngoscope 99: 117–124.

  4. Fischbach, W., Meyer, T. h. & Barthel, K. (1990). Squamous cell carcinoma antigen in the diagnosis and treatment follow-up of oral and facial squamous cell carcinoma. Cancer 65: 1321–1324.

  5. Gleich, L. L., Srivastava, L. & Gluckmann, J. L. (1996). Plasma platelet-derived growth factor: preliminary study of a potential marker in head and neck cancer. Ann Otol Rhinol Laryngol 105: 710–712.

  6. Kawano, Y., Noma, T. & Yata, J. (1994). Regulation of human IgG subclass production by cytokines. IFN-γ and IL-6 act antagonistically in the induction of human IgG1 but additively in the induction of IgG2. J Immunol 153: 4948–4958.

  7. Koch, T., Eiffert, H. & Spindler, M. B. (1989). Die Relevanz des neuen Tumormarkers SCC (Squamous Cell Carcinoma Antigen) für die Diagnostik und Verlaufskontrolle von Plattenepithelkarzinomen im Kopf-Hals-Bereich. HNO 37: 454–459.

  8. Kronberger, L. Jr, Weblacher, M., Estelberger, W., Hauser, H., Schauenstein, E., Schauenstein, K., Smola, M. & Steindorfer, P. (1994). Pre- and postoperative analysis of serum IgG1 in patients with benign and malignant breast diseases. In 2nd European Congress on Senology Kubista E, Staffen A and Zielinski Ch (eds) pp 479–485. Monduzzi Editore, International Proceedings Division, Bologna, Italy

  9. Maninger, K., Schauenstein, K., Weblacher, M., Tillian, H. & Schauenstein, E. (1994). Shift in IgG subclasses – a sensitive early marker for malignant proliferation in tumor bearing rats as a representative model for human cancer. Cancer Mol Biol(CMB) 1: 165–171.

  10. Maninger, K., Weblacher, M., Zatloukal, K., Estelberger, W., Schauenstein, K. & Schauenstein, E. (1994). IgG1 – as the only subclass of human serum IgG – spontaneously undergoes O2-induced, noncovalent self-aggregation upon storage at room temperature. Free Radical Biol Med 20: 263–270.

  11. Maran, A. G. D., Wilson, J. A. & Gaze, M. N. (1993). The nature of head and neck cancer. Europ Arch Oto-Rhino-Laryngol 250: 127–132.

  12. Schauenstein, E., Dachs, F., Reiter, M., Gombotz, H. & List, W. (1986). Labile disulfide bonds and free thiol groups in human IgG. I. Assignment to IgG1 and IgG2. Int Arch Allergy Immun 80: 174–179.

  13. Schauenstein, E., Lahousen, M., Weblacher, M., Steinschifter, W., Estelberger, W. & Schauenstein, K. (1996). Selective decrease in serum immunoglobulin G1 – a tissue non specific tumour marker detecting early stages of gynecological malignant diseases with high efficiency. Cancer 78: 511–516.

  14. Schauenstein, E., Rabl, H., Steinschifter, W., Hirschmann, C., Estelberger, W. & Schauenstein, K. (1997). Selective decrease of serum immunoglobulin G1 as a marker of malignant transformation in colorectal tissue. Cancer 79: 1482–1486.

  15. Silverman, N. A., Alexander, J. C. & Chretien, P. B. (1976). CEA levels in head and neck cancer. Cancer 37: 2204–2211.

  16. UICC, T. N. M. (1992). Classification of malignant tumors, 4th ed, Sobin LH, Wittekind CH (eds). John Wiley & Sons Inc.: New York

  17. Walther, E. K., Dahlmann, N. & Gorgulla, H. T. (1990). Tumormarker bei Patienten mit Kopf-Hals-Karzinomen. Laryngo-Rhino-Otol 69: 271–274.

  18. Weblacher, M., Leitsberger, A., Tillian, H., Maninger, K., Estelberger, W., Schauenstein, K. & Schauenstein, E. (1993). A decrease in reactive disulfide bonds of serum IgG signals a characteristic change in the IgG subclass pattern of rats bearing experimental tumors. Int Arch Allergy Immunol 102: 340–346.

Download references

Author information

Rights and permissions

From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/

Reprints and Permissions

About this article

Cite this article

Anderhuber, W., Steinschifter, W., Schauenstein, E. et al. The IgG1/G2 subclass shift – a sensitive, tissue non-specific marker for malignancy. Diagnostic performance with squamous cell carcinoma of the head and neck. Br J Cancer 79, 1777–1781 (1999) doi:10.1038/sj.bjc.6690283

Download citation

Keywords

  • squamous cell carcinoma
  • head-neck region tumours
  • tumour marker
  • IgG subclasses

Further reading